Zhaoke Ophthalmology Ltd
06622
Company Profile
Business description
Zhaoke Ophthalmology Ltd is a ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address significant unmet medical needs. The company has three flagship drug assets processing towards potential market approval NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two promising drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Mainland China, South Korea, and Others.
Contact
No. 1 Meide 3rd Road
Pearl River Industrial Park
Nansha District
Guangdong Province
Guangzhou
CHNT: +86 2039062828
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
249
Stocks News & Analysis
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
stocks
Bookworm: Is this the secret to exceptional long-term returns?
Acceptance may be an investor’s best friend.
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,934.30 | 45.10 | -0.50% |
| CAC 40 | 7,834.58 | 16.30 | 0.21% |
| DAX 40 | 24,217.50 | 78.43 | -0.32% |
| Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
| FTSE 100 | 9,120.31 | 18.06 | -0.20% |
| HKSE | 25,388.35 | 278.83 | -1.09% |
| NASDAQ | 21,108.32 | 50.36 | 0.24% |
| Nikkei 225 | 41,456.23 | 370.11 | -0.88% |
| NZX 50 Index | 12,853.46 | 48.33 | 0.38% |
| S&P 500 | 6,388.64 | 25.29 | 0.40% |
| S&P/ASX 200 | 8,666.90 | 42.50 | -0.49% |
| SSE Composite Index | 3,593.66 | 12.07 | -0.33% |